Rubius Therapeutics Inc (NASDAQ:RUBY) has been assigned an average recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $37.00.
A number of brokerages have recently commented on RUBY. Zacks Investment Research raised Rubius Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 7th. Morgan Stanley lowered their price target on Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, December 19th. Finally, ValuEngine cut Rubius Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 21st.
Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $44,000. New York State Common Retirement Fund bought a new stake in Rubius Therapeutics during the 4th quarter worth approximately $116,000. American International Group Inc. bought a new stake in Rubius Therapeutics during the 3rd quarter worth approximately $194,000. Rhumbline Advisers bought a new stake in Rubius Therapeutics during the 3rd quarter worth approximately $207,000. Finally, LPL Financial LLC bought a new stake in Rubius Therapeutics during the 4th quarter worth approximately $162,000. 81.24% of the stock is owned by institutional investors.
Shares of RUBY stock traded up $0.08 on Friday, reaching $13.91. The company had a trading volume of 720 shares, compared to its average volume of 207,264. The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.06. Rubius Therapeutics has a 12 month low of $12.70 and a 12 month high of $33.01.
Rubius Therapeutics (NASDAQ:RUBY) last announced its quarterly earnings results on Tuesday, November 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). As a group, research analysts expect that Rubius Therapeutics will post -1.75 EPS for the current year.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Read More: Stop Order
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.